IP Library Granted Patent US 8,927,591
Granted Patent B2
US 8,927,591 · App. 13/128,620 · Granted Jan 6, 2015

Thiochromene derivatives as HIF hydroxylase inhibitors

Inventors: Wen-Bin Ho (Los Altos, CA); Lee R. Wright (Redwood City, CA); Eric D. Turtle (Belmont, CA); Craig Mossman (Saratoga, CA); Lee A. Flippin (Woodside, CA)
Assignee: Fibrogen, Inc.
C07D335/06C07D409/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,591
App. No.
13/128,620
Granted
Jan 6, 2015
Kind
B2
Abstract

The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

Claims (151)

1. A compound of Formula I:

wherein:

q is 1, 2, 3, or 4;

y is 0-2;

R 1 is selected from the group consisting of —OR 18 , hydroxy, acyloxy, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, thio, alkylthio, substituted alkylthio, cycloalkylthio, substituted cycloalkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, heterocyclicthio, substituted heterocyclicthio, amino, substituted amino, and acylamino;

R 2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;

R 3 is selected from the group consisting of hydrogen, deuterium, alkyl, and substituted alkyl;

R 4 is selected from the group consisting of hydrogen, deuterium, and methyl;

each R 5 is independently selected from the group consisting of cyano, acyl, substituted amino, acylamino, sulfonyl, substituted sulfonyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyloxy, substituted heterocyclyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, alkylthio, substituted alkylthio, cycloalkylthio, substituted cycloalkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, heterocyclicthio, substituted heterocyclicthio, heteroaryl, and substituted heteroaryl;

or two R 5 taken together with the carbon atoms to which they are attached form a 5- or 6-membered aryl or substituted aryl;

R 10 is —NR 11 R 12 or —OR 13 ;

R 11 and R 12 are independently selected from the group consisting hydrogen, alkyl, alkylene-cycloalkyl, heterocyclic, and aryl;

or R 11 and R 12 are taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl;

R 13 is selected from the group consisting of a cation, hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl; and

R 18 is a cation;

or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, or tautomer thereof.

2. The compound of claim 1 , wherein R 2 is hydrogen.

3. The compound of claim 1 , wherein q is 1 or 2.

4. The compound of claim 1 , wherein R 1 is hydroxy.

5. The compound of claim 1 , wherein R 1 is hydroxy and R 2 is hydrogen.

6. The compound of claim 1 , wherein R 1 is hydroxy; and R 4 and R 2 are hydrogen.

7. The compound of claim 1 , wherein each R 5 is independently selected from the group consisting of acylamino, substituted alkyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl.

8. The compound of claim 1 , wherein R 5 is selected from a (C 1 -C 3 )-alkynyl, or (C 1 -C 3 )-cycloalkyl; each of which is optionally substituted with an aryl.

9. The compound of claim 1 , wherein R 5 is (C 1 -C 6 )-alkoxy, which is optionally substituted with a cycloalkyl or aryl.

10. The compound of claim 1 , wherein each R 5 is independently selected from the group consisting of aryl and heteroaryl; each of which is optionally substituted with at least one of methoxy, chloro, fluoro or trifluoromethyl.

11. The compound of claim 1 , wherein two R 5 taken together with the carbon atoms to which they are attached form a 5- or 6-membered aryl or substituted aryl.

12. The compound of claim 11 , wherein the aryl is phenyl.

13. The compound of claim 1 , wherein

R 10 is —OR 13 ; and

R 13 is selected from the group consisting of a cation, hydrogen, and alkyl; each of which is optionally substituted with one or more substituents selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl.

14. The compound of claim 1 , wherein

R 1 is hydroxy;

R 2 and R 4 are hydrogen;

R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and

each R 5 is independently selected from the group consisting of acylamino, substituted alkyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl.

15. The compound of claim 1 , wherein

q is 1 or 2;

R 1 is hydroxy;

R 2 and R 4 are hydrogen;

R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;

each R 5 is independently selected from the group consisting of acylamino, substituted alkyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl; and

R 10 is —OR 13 ; wherein R 13 is hydrogen or alkyl.

16. The compound of claim 1 , wherein

q is 1;

R 1 is hydroxy;

R 2 and R 4 are hydrogen;

R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and

R 10 is —OR 13 ; wherein R 13 is hydrogen or alkyl.

17. The compound of claim 1 , wherein

q is 1 or 2;

R 1 is hydroxy;

R 2 , R 3 and R 4 are hydrogen;

each R 5 is independently selected from the group consisting of acylamino, substituted alkyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl; and

R 10 is —OR 13 ; wherein R 13 is hydrogen or alkyl.

18. A compound of Formula II:

wherein

R 2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;

R 3 is selected from the group consisting of hydrogen, deuterium, alkyl, and substituted alkyl;

R 4 is selected from the group consisting of hydrogen, deuterium, and methyl;

R 14 , R 15 , R 16 and R 17 are independently selected from the group consisting of hydrogen, cyano, acyl, substituted amino, acylamino, sulfonyl, substituted sulfonyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyloxy, substituted heterocyclyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, alkylthio, substituted alkylthio, cycloalkylthio, substituted cycloalkylthio, arylthio, substituted arylthio, heteroarylthio, substituted heteroarylthio, heterocyclicthio, substituted heterocyclicthio, heteroaryl, and substituted heteroaryl;

or R 14 and R 15 , R 15 and R 16 , or R 16 and R 17 are taken together with the carbon atoms to which they are attached to form a 5- or 6-membered aryl or substituted aryl;

R 10 is —NR 11 R 12 or —OR 13 ;

R 11 and R 12 are independently selected from the group consisting hydrogen, alkyl, alkylene-cycloalkyl, heterocyclic, and aryl;

or R 11 and R 12 are taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl; and

R 13 is selected from the group consisting of a cation, hydrogen and alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl;

or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, or tautomer thereof;

provided that at least one of R 14 , R 15 , R 16 and R 17 is other than hydrogen.

19. The compound of claim 18 , wherein R 14 and R 17 are independently selected from the group consisting of hydrogen, substituted alkyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

20. The compound of claim 18 , wherein R 15 and R 16 are independently selected from the group consisting of hydrogen, acylamino, substituted alkyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl.

21. The compound of claim 18 , wherein R 2 is hydrogen.

22. The compound of claim 18 , wherein R 4 is hydrogen.

23. The compound of claim 18 , wherein R 2 and R 4 are hydrogen.

24. The compound of claim 18 , wherein R 3 is selected from the group consisting of hydrogen and methyl.

25. The compound of claim 18 , wherein R 2 , R 3 , and R 4 are hydrogen.

26. The compound of claim 18 , wherein R 10 is —OR 13 .

27. The compound of claim 18 , wherein R 10 is —OR 13 ; and R 13 is hydrogen, or alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl.

28. The compound of claim 18 , wherein R 10 is —OR 13 ; and R 13 is C 1 -C 4 alkyl.

29. The compound of claim 18 , wherein R 10 is —OR 13 ; and R 13 is hydrogen.

30. The compound of claim 18 , wherein

R 2 and R 4 are hydrogen;

R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and

R 14 , R 15 , R 16 and R 17 are independently selected from the group consisting of hydrogen, acylamino, substituted alkyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl.

31. The compound of claim 18 , wherein

R 2 and R 4 are hydrogen;

R 3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;

R 14 , R 15 , R 16 and R 17 are independently selected from the group consisting of hydrogen, acylamino, substituted alkyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, alkoxy, substituted alkoxy, heteroaryl, and substituted heteroaryl; and

R 10 is —OR 13 ; wherein R 13 is a cation, hydrogen or alkyl.

32. The compound of claim 18 , wherein

R 2 , R 3 , and R 4 are hydrogen;

R 14 and R 17 are independently selected from the group consisting of hydrogen, substituted alkyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

R 15 and R 16 are independently selected from the group consisting of hydrogen, substituted alkyl, alkoxy, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and

R 10 is —OR 13 ; wherein R 13 is hydrogen or alkyl.

33. The compound of claim 18 , wherein

R 2 , R 3 , and R 4 are hydrogen;

R 14 and R 15 taken together with the carbon atoms to which they are attached form a 5- or 6-membered aryl or substituted aryl;

R 16 is selected from the group consisting of hydrogen, substituted alkyl, alkoxy, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

R 17 is selected from the group consisting of hydrogen, and alkoxy; and

R 10 is —OR 13 ; wherein R 13 is hydrogen.

34. The compound of claim 18 , wherein

R 2 , R 3 , and R 4 are hydrogen;

R 14 is selected from the group consisting of hydrogen, and alkoxy;

R 15 is selected from the group consisting of hydrogen, substituted alkyl, alkoxy, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

R 16 and R 17 taken together with the carbon atoms to which they are attached form a 5- or 6-membered aryl or substituted aryl; and

R 10 is —OR 13 ; wherein R 13 is hydrogen.

35. A compound selected from the group consisting of

[(4-hydroxy-7-methoxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(4-hydroxy-6,7-dimethoxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

{[4-hydroxy-7-(4-methoxy-phenyl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-7-(3-methoxy-phenyl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-7-(2-methoxy-phenyl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[7-(3,5-dichloro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-2-oxo-7-(4-trifluoromethyl-phenyl)-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

[(4-hydroxy-2-oxo-7-phenyl-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

{[7-(4-fluoro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

[(4-hydroxy-2-oxo-7-pyrimidin-5-yl-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(4-hydroxy-2-oxo-7-pyridin-3-yl-2H-thiochromene-3-carbonyl)-amino]-acetic acid, sodium salt;

{[7-(5-fluoro-pyridin-3-yl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[7-(3-chloro-4-fluoro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

[(4-hydroxy-7-naphthalen-2-yl-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(4-hydroxy-2-oxo-7-p-tolyl-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(7-benzyl-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(1-hydroxy-3-oxo-3H-4-thia-phenanthrene-2-carbonyl)-amino]-acetic acid;

[(1-hydroxy-3-oxo-3H-benzo[f]thiochromene-2-carbonyl)-amino]-acetic acid;

[(7-butoxy-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

{[7-(3,5-bis-trifluoromethyl-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[7-(3-fluoro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

2-(S)-{[7-(3-fluoro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-propionic acid;

{[4-hydroxy-2-oxo-7-(2-trifluoromethyl-phenyl)-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[6-(3,5-bis-trifluoromethyl-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-2-oxo-6-(2-trifluoromethyl-phenyl)-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-6-(4-methoxy-phenyl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[6-(2-chloro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[6-(3-fluoro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[6-(4-fluoro-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-6-(2-methoxy-phenyl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-2-oxo-6-(4-trifluoromethoxy-phenyl)-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

[(6-benzoylamino-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(8-benzyl-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

{[8-(3,5-bis-trifluoromethyl-phenyl)-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

{[4-hydroxy-8-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

[(4-hydroxy-2-oxo-8-pyridin-3-yl-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(4-hydroxy-2-oxo-8-phenyl-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(7-cyclopropyl-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

{[4-hydroxy-7-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-acetic acid;

2-(S)-{[4-hydroxy-7-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-2-oxo-2H-thiochromene-3-carbonyl]-amino}-propionic acid;

[(6-benzyloxy-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

[(6-cyclohexylmethoxy-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid; and

and [(6-hexyloxy-4-hydroxy-2-oxo-2H-thiochromene-3-carbonyl)-amino]-acetic acid;

or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, or tautomer thereof.

36. A pharmaceutical composition comprising one or more compounds of claim 1 or 18 and a pharmaceutically acceptable excipient.

37. The composition of claim 36 further comprising at least one additional therapeutic agent selected from the group consisting of vitamin B 12 , folic acid, ferrous sulfate, recombinant human erythropoietin, and an erythropoiesis stimulating agent (ESA).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2011
From: HO, WEN-BIN; WRIGHT, LEE R.; TURTLE, ERIC D.; MOSSMAN, CRAIG; FLIPPIN, LEE A.
To: FIBROGEN, INC.
Reel/Frame 027028/0568 →
Continuity (2)
Provisional Application 61114971 · Nov 14, 2008
Related Publication 20110305776A1 · Dec 15, 2011